61 results about "Prostatic urethra" patented technology

Methods of treating the prostate include administering a thermal ablation therapy and inhibiting the obstruction or closure of the prostatic urethral opening by forming a biodegradable stent in situ in the subject such that the stent attaches to the walls of the prostatic urethra. A related method of treating BPH includes thermally treating or ablating localized tissue in the prostate with a treatment catheter and inserting flowable stent material via the treatment catheter into the prostate (either before, during, or after the thermal treatment), forming the flowable stent material so that it defines a stent that remains in position after removal of the treatment catheter to inhibit the closure of the urinary passage. Associated stents and catheters are included.

Methods, systems, and computer program products for obtaining a sample in vivo and / or treating a subject include positioning an elongated transurethral catheter in the prostatic urethra of a subject, the catheter having a bladder anchoring balloon, at least one biosample entry port disposed axially away from the bladder anchoring balloon, and an axially extending biosample flow channel in fluid communication with the biosample entry port held internally in the catheter. The anchoring balloon is inflated to position the catheter so that the fluid entry port is proximate the prostatic urethra of the subject and prostatic fluid is suctioned from the prostatic urethra into the biosample entry port and into the biosample flow channel. The catheter can include a thermal treatment balloon and / or dilatation balloon and the suctioned sample can be obtained concurrently with, during, or proximate in time to the applied treatment. The catheter can be configured to allow urine to drain therethrough during the treatment / collection of the sample while keeping the urine isolated from the collected prostatic fluid sample.

Methods of treating the prostate include administering a thermal ablation therapy and inhibiting the obstruction or closure of the prostatic urethral opening by forming a biodegradable stent in situ in the subject such that the stent attaches to the walls of the prostatic urethra. A related method of treating BPH includes thermally treating or ablating localized tissue in the prostate with a treatment catheter and inserting flowable stent material via the treatment catheter into the prostate (either before, during, or after the thermal treatment), forming the flowable stent material so that it defines a stent that remains in position after removal of the treatment catheter to inhibit the closure of the urinary passage. Associated stents and catheters are included.

A prostatic stent is configured as a unitary body which is adapted to reside above the sphincter when in position in the subject includes an elongated tube which extends through the sphincter and outside the body of the subject. The stent is configured to allow natural operation of the sphincter when in position in the subject. The unitary body stent includes a lower inflatable portion which expands to contact tissue and help hold the stent in a desired location during a chronic use period of about 2-14 days. The stent can also include an upper and / or intermediate inflatable portions. A method of inhibiting the obstruction or closure of the prostatic urethral opening includes positioning the stent in the subject such that the unitary body of the stent is in the prostate and resides above the sphincter. A method treating BPH includes thermally ablating localized tissue in the prostate and inserting a post-treatment catheter into the prostate (preferably after an initial healing period) to allow the treated tissue to contour therearound and to maintain the urinary passage open. The stent is configured as a unitary body stent adapted to reside above the sphincter of the subject and to allow substantially normal operation of the sphincter. The stent can include a lower inflatable portion which engages, when expanded, with tissue below the localized treatment region about the membranous urethra (between the sphincter and the verumontanum). The post-treatment catheter is configured to reside in the subject for a period of about 2-14 days after delivery of the thermal ablation treatment or therapy.

Methods, systems, and computer program products for providing thermal therapies or internal thermal massage therapy for treating prostatitis by expanding and contracting a treatment balloon with inflation media and currently applying heat to a portion of the prostatic urethra.

Indwelling body lumen expanders which allow for the maintenance and patency of a body lumen, such as the prostatic urethra to relieve urethral obstruction, are described. Because the one or more expanders are configured to be relatively larger in diameter than the diameter of the body lumen, the expanders may become invaginated into the lumen wall thus enabling the prostheses to avoid fluid exposure which in turn prevent the prostheses from becoming encrusted or calcified.

A self adjusting and / or positioning indwelling urethral device is provided. The device generally includes a prostatic urethral stent body and a urethral anchoring element. The prostatic urethral stent body includes a preconfigured end portion for anchored receipt within a bladder with the urethral anchoring element extending from the prostatic urethral stent body via a linkage. Engagement of the proximal anchor, delimited by the preconfigured end portion of the stent body, with the bladder is no or minimal impact upon the trigone region.

A partial-length catheter, or an extendable tube or sleeve member of the catheter, is selectively movable within the prostatic urethra to open a urine drainage passageway through and obstructed portion of the prostatic urethra or to open the external urinary sphincter muscle and thereby discharge urine from the bladder. A control element is manipulated at a position exterior of the urinary canal to selectively move the catheter or the extendable tube or sleeve member, thereby selectively controlling urine discharge. The catheter may also be used to diagnose urinary retention problems caused by a weak bladder or a prostatic obstruction.

According to an aspect of the invention, urological medical devices are provided, which comprise a prostatically beneficial agent selected from alpha-adrenergic blockers, antispasmodic agents, anticholinergic / antimuscarinic agents, calcium channel blockers, anti-inflammatory agents, hormone-affecting agents, anti-cancer agents, and combinations thereof, among others. The urological medical devices are adapted for implantation or insertion into a subject's urinary tract, whereupon at least a portion of the prostatically beneficial agent is released into the subject's prostatic urethra. The release profile of the prostatically beneficial agent is effective to treat a prostatic disorder, for example, benign prostate hypertrophy, prostate cancer or prostatitis, among others. Other aspects of the invention are directed to treating prostatic disorders.

An implantable biocompatible expander suitable for implantation into a urinary duct, comprises an elongated sinusoidal ring comprising at least two proximal prongs and at least two distal prongs, wherein the expander is resiliently deformable from a relaxed radially expanded orientation to a radially contracted orientation suitable for transluminal delivery through the urinary duct. The expander is configured to exert an outward radial force against a wall of the urinary duct when in-situ within the urinary duct. In particular, the expander is suitable for treatment of benign prostatic hyperplasia and configured for implantation into the prostatic urethra between, and substantially spanning the prostatic urethra between, the bladder neck and external sphincter.

A balloon catheter is provided for the implantation of a stent in a mammalian duct or cavity, comprising an elongate distal section and an expandable first balloon accommodating the section, further comprising means for the supply of a pressure medium for the expansion of the balloon, and means for heating the pressure medium, the catheter being provided with an elongate stent mounted onto the balloon. The catheter contains second means for establishing outwardly directed expansion of the stent at a sight or location selected from the two ends of the stent so that the stent will remain in position as implanted after removal of the catheter from the duct or cavity; and a method for the implantation of a stent in a human prostatic urethra.

This invention relates to a temporary indwelling prostatic stent which provides a passage for urine through the prostatic urethra and which enable the patient to void the bladder at will. This temporary prostatic stent consists of a coiled or braided made out of metal or plastic section which spans the prostatic urethra, wings composed of memory alloy allowing an anchoring means in the bladder, and an anchoring means below the external sphincter, and a retrieval string to facilitate removal of the stent from the patient.

A urethral stent for the prostate including a first stent section placed into an upper portion of the urethra passing through the prostate, a second stent section placed into a lower portion of the urethra below a urinary sphincter muscle, the first and second stent sections being formed of a shape-memory alloy wire, and at least one connection filament is provided at a middle portion of the urethra passing through the urinary sphincter muscle so as to connect the first and second stent sections, thereby preventing the stent from moving to the upper or lower portions of the urethra.

An indwelling catheter for insertion into a patient's urinary tract is provided that includes first and second tubular members that enable drainage of physiological fluids. An inflatable balloon is attached to the second tubular member. The first and second tubular members are interconnected by a connecting tube forming a gap between the first and second tubular members. The connecting tube is in fluid communication with the balloon to enable the balloon to be inflated via the connecting tube. When the balloon is anchored within the urinary bladder the second tubular member is located within the prostatic urethra with one end in close proximity to the sphincter and the other end protruding into the urinary bladder. The first tubular member is located within the penile urethra with one end in close proximity to the sphincter so that the connecting tube traverses the sphincter permitting voluntary control of the sphincter.

A cryosurgical system for assisting an operator in placing and operating cryosurgical probes in the prostate of a human patient. The cryosurgical system includes a computer system being programmed with software capable of performing the following steps: a) capturing a plurality of transverse views of the prostate; b) capturing a sagittal view of the prostate; c) outlining the capsule of the prostate, the urethra and the rectal wall of the patient with the assistance of the operator, utilizing the captured plurality of transverse views and the captured sagittal view; d) constructing a 3-dimensional model of the prostate, the urethra and the rectal wall utilizing the outlines of step c), above; and, e) utilizing the 3-dimensional model of the prostate, the urethra and the rectal wall to determine i) the number of cryosurgical probes to be utilized; ii) probe settings; and, iii) probe placement positions. The resultant ice thus produced by the cryosurgical probes is optimized for a specific patient.

Disclosed herein is a stent for prostatic urethra expansion which does not generate bladder stones, is removable without causing injury on a urethra, and does not generate atrophy of a prostatic urethra even after removal. The stent for prostatic urethra expansion include a stent unit including a cylindrical body with space parts formed by knotting or crossing shape memory alloy wires and bending terminals formed at both ends of the cylindrical body, a pair of hook wires passing through the space parts and knotted to the shape memory alloy wires, both ends thereof being wound on the bending terminals and then being bent upwardly to produce hooks, and a pair of hanging strings arranged in opposite directions to form a hanging knot. The stent for prostatic urethra expansion does not move into the bladder, and expands and maintains a lumen of the stenosed prostatic urethra, thereby reducing post-operative recovery time.

A dilating device for the prostatic urethra comprises: at least three, laterally connected ridges, wherein each ridge is configured to longitudinally engage with a different substantially longitudinal groove of the prostatic urethra of a patient, the at least three laterally connected ridges are configured to laterally compress to enable insertion into the prostatic urethra in a compressed configuration, and the at least three laterally connected ridges are configured to laterally expand to a normally-open configuration upon deployment within the prostatic urethra, to exert a radially outwards force that dilates the prostatic urethra.

The invention is the prostate urethra medicine injection and washing drainage tube, which comprises a tube body, two tube cavities of the prostate urethra part medicine injection and washing drainage tube cavity and a bulboperineal urethra balloon tube cavity are arranged in the tube body; the front part of the tube body is provided with a bulboperineal urethra balloon wrapped around the tube body, the opening on the front end of the bulboperineal urethra balloon tube cavity is communicated with the bulboperineal urethra balloon, and the opening on the tail end thereof is arranged on the tail end of the tube body and is communicated with the outside of the tube body, the tube port of the opening on the tail end is provided with a one-way rubber plug; the opening on the front end of the prostate urethra part medicine injection and washing drainage tube cavity is arranged before the bulboperineal urethra balloon near the tube body wall on the front end of the tube body and is communicated with the outside of the tube body, the opening on the tail end thereof is arranged on the tail end of the tube body and is communicated with the outside of the tube body, the tube port of the opening on the tail end is provided with a one-way rubber plug; the opening on the front end of the prostate urethra part medicine injection and washing drainage tube cavity is 1.0cm-3.0cm far away from the opening on the front end of the bulboperineal urethra balloon tube cavity. The invention cancels the vesical cervix balloon tube cavity and the vesical cervix balloon in the catheter of the prior art, which reduces the diameter of the catheter, relieves the pain of the patient, and the sealing function is better. The invention saves materials, simplifies production art, and reduces production cost, thus the treatment charge is largely reduced for patients. Therefore, the invention is more favorable for clinic promotion compared with the prior art.

An endourethral device is provided having an elongate member having proximal and distal segments, the elongate member positionable within a lower urinary tract so as to at least partially traverses a prostatic urethra. A proximal anchor, adapted to abuttingly engage portions of a bladder neck so as to at least proximally anchor the device, is supported at least indirectly by the proximal segment of said elongate member. The proximal anchor includes bladder engaging elements radially extending from the proximal segment of said elongate member, urine being freely dischargable about at least the proximal segment so as to substantially bathe the bladder neck therewith.

The invention relates to a system and method in which a Foley catheter (70) or other medical tool which is equipped with ultrasound (US) sensor(s) (72) is inserted into the prostatic urethra. Based on analysis of the US signal received by these US sensors (72) as the US beams from a transrectal US (TRUS) probe (40) or other ultrasound probe sweep the field of view, it is possible to precisely detect and track these US sensors (72) in the same frame of reference as the TRUS images, thereby precisely delineating the Foley catheter and the course of the prostatic urethra. During the procedure, before each seed is dropped, the delivered dose to the prostatic urethra can be computed based on real-time tracking and segmentation of prostatic urethra and dose radiation based on previously dropped seeds and if necessary, the procedure can be re-planned automatically.

The invention discloses a magnetic probe steel assembly for urethral reunion operation. The magnetic probe steel assembly comprises first probe steel and second steel, wherein two ends of the first probe steel are a first handheld end and a first magnetic end; the first magnetic end is used for extending in from anterior urethra, passing through a bulb of urethra part and arriving at a membranousurethra breaking position; the end of the first magnetic end has magnetism; a channel allowing a guide wire to pass through is formed in an inner cavity of the first probe steel along the direction ofthe first probe steel; two ends of the second probe steel are a second handheld end and a second magnetic end; the second magnetic end is used for entering prostatic urethra through bladder and arriving at the membranous urethra breaking position; and the end of the second magnetic end has magnetism. According to the magnetic probe steel assembly disclosed by the invention, through cooperation ofthe first probe steel and the second probe steel, an operator is convenient to operate; and through mutual attraction of the first magnetic end and the second magnetic end, the situation that under the attraction of the second probe steel, the first probe steel enters the bladder, and urethral reunion operation is completed is guaranteed.